Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Alaska Clinical Research Center, LLC
Anchorage, Alaska, United States
San Bernardino Urological Associates
San Bernardino, California, United States
Western Clinical Research, Inc.
Torrance, California, United States
Shands Hospital
Gainesville, Florida, United States
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Georgia Urology,PA Research Institute
Atlanta, Georgia, United States
University of Chicago, Section of Hematology/Oncology
Chicago, Illinois, United States
University of Illinois, Department of Urology
Chicago, Illinois, United States
Michiana Hematology/Oncology
South Bend, Indiana, United States
The Urologic Institute of New Orleans
Gretna, Louisiana, United States
Completion Date
June 1, 2004
Last Updated
June 7, 2012
YM598
DRUG
Lead Sponsor
Astellas Pharma Inc
Collaborators
NCT07225946
NCT04868604
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00756665